Raffaele De Caterina – författare
4 524 kr
Skickas inom 10-15 vardagar
6 157 kr
Läs direkt efter köp
2 145 kr
Läs direkt efter köp
2 070 kr
Läs direkt efter köp
2 411 kr
Skickas inom 5-8 vardagar
1 635 kr
Läs direkt efter köp
Bridging the gap between the laboratory and the bedside, this timely volume illuminates the connection between endothelial dysfunction and vascular disease. This comprehensive survey of atherosclerotic disease begins with biology – incorporating the latest breakthroughs in the field – then elucidates risk factors and diagnostic tools and markers. A major section on endothelium-directed prevention and therapy shows you how to apply cutting-edge research to clinical care.
Under the careful editorial guidance of Drs. De Caterina and Libby, the highly-regarded contributors address:
endothelial activation and the initiation of atherosclerosis mechanisms of plaque progression and complications the role of LDL in the origin and progression of atherosclerosis advanced glycation endproducts and the accelerated atherosclerosis in diabetes oxidative stress and vascular disease soluble adhesion molecules as markers of vascular disease hormone-replacement therapy and cardiovascular risk anti-oxidants and endothelial protection and more.The first book dedicated to the central role of endothelial dysfunction in vascular disease, this concise volume gathers all the latest information on the subject into one convenient and cohesive text. Make sure your patients are benefiting from current knowledge by keeping a copy of Enothelial Dysfunctions in Vascular Disease close at hand for frequent consultation.
IntroductionEvery book has a history, this one not excepted, having emerged from intersections in professional lives of the Editors. This book bears the fruits of a collaboration between the “pupil” (RDC) and the “mentor” (PL). During an extended sabbatical of the pupil in Boston in 1994, we probed together the concept that endothelial dysfunction served as a common denominator of vascular disease, with the balance between inflammation and its inhibition as a fulcrum of the regulation of the behavior of endothelial cells. As practicing cardiologists in our clinical lives, we sought to link to endothelial function the mechanisms of action of risk factors and of pharmacologic agents used to treat and prevent vascular disease. The pupil therefore authored a few reviews on the mechanism of action of risk factors and included them in a small book, published in Italian, for which the mentor wrote a preface. The book was greeted with favor from the Italian cardiological community, and provided the nidus for the present, more ambitious endeavor, which includes updated reviews on the pathogenesis of vascular disease and on the most novel aspects of vascular biology. This enterprise was enabled by the contributions of many of our former or present collaborators and colleagues, without whose enthusiasm and engagement this work could never have seen light. We largely underestimated the devotion necessary on our own side at the beginning, but it ultimately yielded a product that we feel achieves our original goals. We are aware that we confront a continuously evolving topic, where frequent updates would be desirable - if not necessary. Yet, we believe in the value of books - such as the current one - that attempt to organize in a snapshot of time, the vast amount of literature available in a coherent and comprehensive scheme. We are aware of existing gaps, of emerging material not paid its due, and of the rapid evolution of some of the concepts highlighted within. The links between the laboratory and the clinic have never afforded more opportunity for new understanding and advances in diagnosis and treatment than today We hope that our colleagues, vascular biologists cardiologists, internists, and other physicians alike will find this compendium a useful guide to this most exciting time in vascular biology and medicine—Raffaele De Caterina and Peter Libby
1 866 kr
Läs direkt efter köp
Managing patients with thrombotic vascular disease is complex and challenging:
Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis—even with the evolution in our understanding of the pathobiology of thrombosis. There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agentsNow more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject.
Written and edited by today’s leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get:
Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies Strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs Updated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction Special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.